Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GC 1118A

Next Previous
Search
Drug Profile

GC 1118A

Alternative Names: Anti-EGFR monoclonal antibody - GC Biopharma; GC-1118; GC1118A

Latest Information Update: 15 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Green Cross; National Cancer Center (Korea)
  • Developer GC Biopharma; National Cancer Center (Korea)
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Adenocarcinoma; Colorectal cancer; Glioblastoma
  • Phase I/II Gastric cancer

Most Recent Events

  • 05 Apr 2024 Interim efficacy data from a phase-II trial in Adenocarcinoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 29 Mar 2022 GC Pharma is now called GC Biopharma
  • 05 Mar 2021 Phase-II clinical trials in Colorectal cancer (Combination therapy, Metastatic disease, Recurrent, Second-line therapy or greater) in South Korea (IV) (GC Pharma pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top